Diplomat to dispense Zejula

FLINT, Mich. — Diplomat Pharmacy on Wednesday announced that it had been selected to the specialty pharmacy panel dispensing Zejula (niraparib). The drug is a once-daily oral maintenance treatment indicated to treat women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

 

Zejula is the first poly ADP-ribose polymerase inhibitor approved by the Food and Drug Administration that doesn’t require BRCA mutation or other biomarker testing, Diplomat said.

 

“For women living with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, Zejula (niraparib) offers new hope as a promising treatment option,” said Paul Urick, Diplomat’s president.